Navigation Links
Cellular Biomedicine Group Appoints Director of Medical Research
Date:7/11/2013

PALO ALTO, Calif., July 11, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Maxwell Wang, M.D., PhD, as Director of Medical Research.

Dr. Wang received his MD degree from Wuerzburg University in Germany and PhD degree from University of Aberdeen, UK, following which he continued extensive research at the University of Connecticut Health Center. During his academia Dr. Wang was the first to find the paracrine and autocrine effects of CCN family genes (genes relating to connective tissue growth) in bone cell differentiation and the capability of  bone marrow-derived CTGF-GFP cells to increase bone formation. Dr. Wang is an orthopedic surgeon with over 10 years of experience in academic research focused on mesenchymal stem cells and bone cells.

Dr. Chase Dai, VP and GM of CBMG's Autologous Products Business Unit, commented, "Dr. Wang's extensive experience in the field of stem cells, particularly as applied to orthopedics, will be a valuable asset to our Knee Osteoarthritis program which is currently in clinical trial."

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:
Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@cellbiomedgroup.com


'/>"/>
SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer
2. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
3. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
4. Cellular Dynamics International Opens Facility in California, Leasing Space from the Buck Institute to Derive and Bank Human Induced Pluripotent Stem Cells
5. Cellular Biomedicine Group Marks the Launch of China Clinical Trial for TC-DC Therapy for Hepatocellular Carcinoma
6. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
7. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
8. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
9. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
10. EastBridge Investment Group Announces Merger with Cellular Biomedicine Group
11. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... conjugates market has been growing rapidly as the global sales of ... Globally, the growth in the antibody drug conjugates market is driven ... incidences of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and ...
(Date:3/24/2017)... 2017  GenomeDx Biosciences today announced that six abstracts ... Prostate Cancer Classifier tests will be presented at the ... Congress held March 24 to 28, 2017 in ... is Europe,s largest urological event ... urological field. The abstract titled "Muscle invasive ...
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... spark a conversation on the current obstacles facing infection prevention and offer strategies ... deaths caused by these infections. , The print component of “Fighting Infection” ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in Southlake, ... leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” ... designed to teach how to maximize their sales efforts, as well as how ...
Breaking Medicine News(10 mins):